News

FDA approved Tresiba (insulin degludec injection, Novo Nordisk) and Ryzodeg 70/30 (insulin degludec/insulin aspart injection, Novo Nordisk) for the treatment of diabetes mellitus.

FDA has approved cariprazine (Vraylar, Allergan and Gedeon Richter Plc.) for the treatment of schizophrenia and bipolar I disorder in adults.

Five initiatives, five success stories

Most managed care executives believe they will recoup their investments in population health management (PHM) within four years, but many don’t have a clear vision of the pathway to success

Those who are in decision-making roles must study how other countries address healthcare financing and delivery so as to bring the best initiatives of the studied country to the healthcare systems they oversee.

AstraZeneca recently released positive new data on its experimental non-small cell lung cancer (NSCLC) drug, AZD9291 (osimertinib)

Most payers and employers now offer high-deductible health plans (HDHPs), but questions remain regarding whether these options will actually help plans save on healthcare costs.

Questions remain regarding how those plans will impact hospital revenue.

FDA’s approval of Vertex Pharmaceutical’s groundbreaking lumacaftor/ivacaftor (Orkambi) for cystic fibrosis (CF) is the first drug to treat the underlying cause of CF in people ages 12 and older with two copies of the F508del mutation.

Aspirin should be taken daily in low doses by certain people to not only prevent heart disease and stroke, but also colon cancer, according to new draft guidelines.

If a crisis were to suddenly arise for your organization, would your people be ready to handle it?

While the introduction of the Health Insurance Marketplace plans in 2014 has accelerated the trend of more Americans with HDHPs, the number of such plans was already increasing before then.

Blue Cross Blue Shield of Michigan (BCBSM) is collaborating with the University of Michigan Health System, physician organizations and pharmacists across the state to team up pharmacists with patient care teams as part of a new initiative to help patients manage and comply with their medication plans.

A deeper dive into the proposed payer mergers reveals how they could impact market dynamics.

The latest specialty drug pricing debate centers around Daraprim for toxoplasmosis infections, the price of which skyrocketed 5,000% within a month.

The U.S. Department of Health and Human Services’ Office of the Assistant Secretary for Preparedness and Response (ASPR) and Regeneron Pharmaceuticals in Tarrytown, New York, are partnering to develop a novel Ebola virus treatment.

Christopher Kerns, MBA, managing director, Research and Insights, The Advisory Board Company, believes high-deductible health plans (HDHPs) will help foster high-value healthcare.

Here are seven tips healthcare leaders must keep in mind when speaking to the press.

Beyond the obvious training and work flow challenges associated with the ICD-10 transition, a whole host of challenges will arise as ICD-10 becomes the new reality.

FDA announced new requirements for the monitoring, prescribing, and dispensing of clozapine, an atypical antipsychotic for treatment-resistant schizophrenia, due to the continued risk of severe neutropenia, which can be life-threatening.

HealthSpot’s telebooths, which are currently in more than 20 Rite-Aid stores, are changing how patients interact with healthcare. Find out how it works.

A recent study projects that U.S. employers may see minimal savings to overall healthcare costs resulting from the introduction of biosimilars to the U.S. market.

A coalition is opposing the Access to Quality Diabetes Education Act of 2015, saying it limits access to care. Here's why, and how the American Association of Diabetes Educators (AADE) is responding.

A recent report evaluates the "true cost" of the 340B program. Read the key findings.

While Affordable Care Act has created huge opportunities for payers, most of those opportunities cannot be leveraged to their full advantage using 20th century strategies.

While biosimilars’ savings will not reach the historically high level achieved for small-molecule generic drugs, the impact on the healthcare industry will still be significant, according to a new report.

Joint FDA advisory committees voted 23-1 against approving Purdue Pharma’s immediate release opioid painkiller Avridi last week.

FDA has expanded approval for ticagrelor (Brilinta, AstraZeneca) to include long-term use in patients with a history of heart attack.